Homo sapiens
Protocols: This prospective study was carried out at the IBD center of the University Hospitals Leuven (Leuven, Belgium). Endoscopy-derived inflamed colonic biopsies were obtained from IBD patients initiating biologic therapy (vedolizumab, adalimumab or infliximab). All patients had active disease, endoscopically proven, and they all had to be naïve for the drug that was initiated at inclusion. All biopsies were taken at the most affected site, at the edge of the ulcerative surface. Biopsies were taken during endoscopy prior to the start of therapy, stored in RNALater buffer (Ambion, Austin, TX, USA) and preserved at -80°C. Patients received vedolizumab 300mg at baseline, week 2 and week 6, with subsequent administration every 8 weeks. All CD patients received an additional infusion at week 10. Total RNA from inflamed biopsies was extracted using the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The integrity and quantity of all RNA was assessed with a 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and a Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Extracted RNA was stored at -80°C until further processing. Library preparation using the TruSeq Stranded mRNA protocol (Illumina, San Diego, USA) according to the manufacturer's instructions.
ENA-FIRST-PUBLIC
2019-08-23T17:03:46Z
ENA-LAST-UPDATE
2019-04-03T10:59:11Z
External Id
SAMEA5547839
INSDC center name
Department of Gastroenterology, University Hospitals Leuven, KU Leuven, Leuven, Belgium Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium
INSDC first public
2019-08-23T17:03:46Z
INSDC last update
2019-04-03T10:59:11Z
INSDC status
public
Submitter Id
E-MTAB-7845:GC050292
broker name
ArrayExpress
clinical information
response to vedolizumab therapy
common name
human
developmental stage
adult
disease
ulcerative colitis
organism part
colonic mucosa
sample name
E-MTAB-7845:GC050292
scientific_name
Homo sapiens